about
Heroin-assisted treatment (HAT) a decade later: a brief update on science and politicsCost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials.Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials.Depot-medication compliance for patients with psychotic disorders: the importance of illness insight and treatment motivation.Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies.Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients' and clinicians' perspectives after a 12-month randomized controlled trial.Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial.Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials.Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands.Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence.Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence.Criminal involvement and crime specialization among crack users in the Netherlands.Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population.Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls.Efficacy of cocaine contingency management in heroin-assisted treatment: Results of a randomized controlled trial.Physical and mental health and social functioning in older alcohol-dependent inpatients: the role of age of onset.Craving and illicit heroin use among patients in heroin-assisted treatment.Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial.Attentional bias predicts heroin relapse following treatment.Patterns of acquisitive crime during methadone maintenance treatment among patients eligible for heroin assisted treatment.Cue exposure therapy for the treatment of opiate addiction: results of a randomized controlled clinical trial.Treatment of adolescents with a cannabis use disorder: main findings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands.Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands.Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients.The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trialClinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial
P50
Q24643474-23A1C3BC-6F75-45D8-A4F0-13D7DFE5F51CQ33940904-AC47EBA8-CE67-4C77-8C2F-66C819871360Q34650576-13410FFD-4C1D-4D7C-A321-453D5886DB57Q35218513-AE76D1D5-F723-46E5-A02C-3EBB020048BBQ38287203-89222922-DDF2-4AB0-9F90-400AF1EE17E9Q38348311-A8B0676F-CD67-425E-AE42-0E4692D3E417Q38603405-A346E5D5-0A55-450B-983C-560A4E8E7E06Q38871336-FB8097A5-F737-4EBF-96CE-16DFAC36D101Q38890059-919D2E83-2F87-40EA-BA1C-5C7A35085EB8Q38942444-127BEF67-F4A6-499D-8D01-6CF87AF2A39BQ42642615-ED4792EB-B741-45FB-8859-19BE6E7A866AQ43239530-5C78DF31-0404-41E5-823F-4A1C2A94B897Q44340328-592CFC49-A72B-4BA6-929F-72566A1964C2Q44348462-F9B6E0E9-0EFB-4073-9EBE-43F3246EFAA2Q44768135-2AF0DAE2-08F2-4B63-8D7D-08525E0ED4C8Q46707974-B8F5176A-515D-4C2F-879A-2C831274AF2BQ47360280-851880A3-B16B-4D3C-BAEE-DDEFB6AA70B3Q47431078-DD27C5CA-046C-459D-A250-3C664DDBB397Q48078110-9E1C4D4A-34EE-454D-AF8D-11B9587C59B8Q50793263-34E4F6FE-E8EB-4285-B48C-C86186D948C2Q50927123-BFF74146-91DC-44F7-8B46-410BDE7E990CQ51913668-92396E41-72E2-4D44-9738-1E50C3D0C202Q51915515-B76E051F-E606-4D29-9BDE-B8E34B20C88FQ52290602-88907741-589B-4B77-9DAB-762CE416FDF9Q52298905-8DB64F30-4276-4793-848F-CDAC5942244BQ52304268-C403E38C-63E2-4390-B49E-2B29F49BEC47Q53832463-9E32D3D0-BC6F-4133-B64E-5C67BF89ECBAQ55009590-57355DDD-C65D-4C1C-A9F0-857D8D01E20AQ58755285-B256EE8D-F3DE-47C5-B14A-BA6441831406Q92458554-D370B8E5-90B1-4948-B571-20B568F0346C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter Blanken
@ast
Peter Blanken
@en
Peter Blanken
@es
Peter Blanken
@nl
Peter Blanken
@sl
type
label
Peter Blanken
@ast
Peter Blanken
@en
Peter Blanken
@es
Peter Blanken
@nl
Peter Blanken
@sl
prefLabel
Peter Blanken
@ast
Peter Blanken
@en
Peter Blanken
@es
Peter Blanken
@nl
Peter Blanken
@sl
P1053
J-4209-2012
P106
P21
P31
P3829
P496
0000-0003-4847-4259